About us
CliniKids is a not-for-profit centre integrating world-class research with a clinical service for children with developmental delay and/or an autism diagnosis, and their families. It is the first of its kind for autism in Australia.
To give you the best experience, this site uses cookies. Learn more about cookies
CliniKids is a not-for-profit centre integrating world-class research with a clinical service for children with developmental delay and/or an autism diagnosis, and their families. It is the first of its kind for autism in Australia.
CliniKids provides therapy support and individualised programs to help children and families to reach their full potential.
One of the unique aspects of CliniKids is the integration of clinical services with cutting-edge research. Our exceptional team of researchers work in collaboration with our clinicians to give the community access to the world's best evidence-based therapies.
Here you'll find a wealth of information and resources to help support your child on the autism spectrum.
Find out about many of our previous research studies and trials, and those that are ongoing but are no longer recruiting participants.
The aim of this research program was to test the efficacy of the parent-led iBASIS-VIPP program for improving the developmental outcomes for babies aged 9 to 14 months of age showing early signs of autism, such as social and communication delays. Find out more about AICES here.
The aim of this study was to evaluate the effectiveness of an app-based game designed by our team and The University of Western Australia to improve social information in children on the autism spectrum.
The use of fish oil supplements as part of daily dietary intake is very common among children with autism. Some evidence suggests that omega-3 fatty acids found in fish oil are important for brain development and may be of significant benefit to autistic children.
Fluoxetine belongs to a class of medications known as the Selective Serotonin Reuptake Inhibitors (SSRIs) which are thought to help in treating repetitive behaviours. It is therefore important for us to know that fluoxetine is effective in treating repetitive behaviours in children diagnosed with autism.
The TOBY trial was a multisite randomised controlled trial that looked at determining the effectiveness of the TOBY (Therapy Outcomes By You) Playpad application (app) as a complement to existing therapy and to examine the attitudes and beliefs of parents towards the TOBY app as an intervention method.
The aim of the Beyond Childhood study was to gain an understanding of autism across the life-course. The WA Autism Register was developed in 1999 and collected data from children with autism at the time of diagnosis.
We are now seeking to make another important advance by recontacting individuals on the Autism Register who gave their contact details at the time of their child’s diagnosis.
Our aim was to see how children have changed since they were diagnosed, and understand their achievements and challenges over time.
The development of National Guideline for the Assessment and Diagnosis of Autism in Australia.
The aim of the Australian Autism Biobank was to collect detailed information on children diagnosed with autism and their families in Australia and to centralise the information so that it is accessible to those who are involved in autism research. Recent research, led by Mater Research and the University of Queensland and involving Telethon Kids Institute researchers, found that individuals with autism had less diverse gut bacteria because they were more likely to be picky eaters.
The aim of this study was to determine whether children on the autism spectrum have different facial features to typically developing children and to determine whether children with certain behaviours are more likely to have facial anomalies.
The PRISM study compared pregnancies in which the mother has had a previous child with autism to pregnancies in which there is no family history of autism.
Our exceptional team of researchers work in collaboration with our clinicians and give the community access to the very best evidence-based therapies in the world.
See what current research studies are currently recruiting.